Navigation Links
ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
Date:11/8/2011

pared to placebo at Week 12 (p=0.023).  ACR50, ACR70, DAS28-CRP, and ACR component results indicated greatest efficacy in the 200 mg daily dose group.  Decreases in bone turnover markers C-telopeptide (CTx), procollagen type I N-terminal propeptide (PINP), and osteocalcin were more pronounced in the CCX354-C groups compared to placebo, and reaching statistically significant improvements at many time points during the study. Clinical responders had higher plasma CCX354 concentrations than non-responders.  CCX354 was well tolerated by patients in this study.

Study DesignThis Phase II study named CARAT-2 (CCR1 Antagonist in Rheumatoid Arthritis Trial-2) was a 160-patient multinational, randomized, double-blind, placebo-controlled RA clinical trial.  Patients had moderate to severe RA, were on stable methotrexate treatment for at least 8 weeks, had >/= 8 swollen and tender joint counts, and CRP >/= 5 mg/L at study entry.  Patients received double-blind placebo twice daily (N=54), 100 mg CCX354 twice daily (N=53) or 200 mg CCX354 once daily (N=53) orally for 12 weeks.  Safety and tolerability were primary endpoints, and secondary endpoints included RA disease response measurements:  ACR, DAS28, CRP, and ESR, as well as bone turnover markers, CTx, PINP, and osteocalcin.

CCX354 and Rheumatoid Arthritis (RA)CCX354 is a potent and selective antagonist of CCR1, a chemokine receptor that drives the recruitment of certain inflammatory cells including populations of monocytes and macrophages into the joints of patients with RA.  By selectively blocking the CCR1 receptor, CCX354 is designed to reduce the infiltration of inflammatory cells into the joints of RA patients and inhibiting the inflammation, swelling, pain and associated joint destruction while minimizing the potential for off-target effects, thus providing a wider therapeutic window than currently approved thera
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
2. ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
3. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
4. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
6. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
7. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
10. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
11. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , August 27, 2015 According to ... (Transfer, Hammock, Toilet, Seating, Universal, Standing, Bariatric ), Material (Nylon, Padded, ... Forecast to 2020", published by MarketsandMarkets, the Medical Lifting Sling Market ... 411.5 Million in 2015, at a CAGR of 11.4 % from ... ma rket data T ables and ...
(Date:8/27/2015)... Ga. , Aug. 27, 2015  MiMedx Group, ... medicine company utilizing human amniotic tissue and patent-protected ... therapies for the Wound Care, Surgical, Orthopedic, Spine, ... responded today and corrected the multiple inaccuracies in ... Foundation ("MTF") regarding the recent rulings from the ...
(Date:8/27/2015)... August 27, 2015 According to ... by Type (Integrated, Standalone), by Deployment Mode (Web based, ... Emergency Healthcare Service Providers), by Component - Global Trends ... Market is estimated at $501.1 Million 2014, and is ... CAGR of 7.6% from 2014 to 2019. ...
Breaking Medicine Technology:Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 4Radiology Information Systems Market Worth $722.7 Million by 2019 2Radiology Information Systems Market Worth $722.7 Million by 2019 3Radiology Information Systems Market Worth $722.7 Million by 2019 4
... PRXL ) announced today it will be presenting ... von Rickenbach, Chairman and Chief Executive Officer will be making ... January 13, 2011. A live webcast of this ... of PAREXEL,s website at www.PAREXEL.com in the Upcoming ...
... Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be presenting ... Francisco on Monday, January 10, 2011 at 4:30 p.m. ET ... and chief executive officer of Amylin Pharmaceuticals, will provide a ... be webcast through the "Investors" section of Amylin,s corporate website ...
Cached Medicine Technology:PAREXEL International to Present at J.P. Morgan Healthcare Conference 2
(Date:8/27/2015)... ... 27, 2015 , ... Zensah®, the premium athletic compression company, ... Israel in the Women’s Tennis Association (WTA). Glushko competes in tennis tournaments around ... With a focus on technology and comfort, Zensah® has developed compression gear to ...
(Date:8/27/2015)... and OKLAHOMA CITY, OK (PRWEB) , ... August ... ... Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract development manufacturing ... be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
(Date:8/27/2015)... ... August 27, 2015 , ... Susan Harris and ... relieve vaginal discomfort due to pre- and post-menopause, chemotherapy, and child birth. , ... which delivers controlled energy to the vaginal tissue, revitalizing cells so they make more ...
(Date:8/27/2015)... ... August 27, 2015 , ... NetDimensions is once again named among ... platforms required not only to effectively deliver, curate and administer great programs, but also ... , For six consecutive years, NetDimensions has maintained its position on this Top ...
(Date:8/27/2015)... Winchester, MA (PRWEB) , ... ... ... Group, Inc., an executive management consulting firm that helps libraries, publishers and ... DuraSpace Registered Service Provider (RSP) for the VIVO Project. Gunter Media Group, ...
Breaking Medicine News(10 mins):Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 2Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 3Health News:DuraSpace Selects Gunter Media Group, Inc. as a Registered Service Provider for VIVO 2Health News:DuraSpace Selects Gunter Media Group, Inc. as a Registered Service Provider for VIVO 3
... 11, 2011) According to new research by University ... treating a variety of diseases may produce unintended and ... Induce Retinal Degeneration via TLR3 and IRF3", appears in ... Therapy, a publication of the Nature Publishing Group ...
... Okla. From the barren arctic tundra to the ... of creatures seems to increase as ambient temperatures rise. ... has ever examined the reasons behind differences in populations ... and Jizhong Zhou, professors in the University of Oklahoma ...
... separated from an abusive partner, the violence still costs Canadians an ... of British Columbia. Led by UBC Nursing Prof. Colleen Varcoe, ... Public Policy is the first in Canada to comprehensively ... who leave a violent partner. Overall, the annual bill ...
... KAMPALA, Uganda A pioneering international collaboration forged ... Wash., USA, together with the Uganda Cancer Institute ... future construction of a state-of-the-art cancer training and ... be the first comprehensive cancer center jointly constructed ...
... Oct. 11, 2011A total of 606 Canadian physicians were ... and 2009, researchers at St. Michael,s Hospital found. ... cent) who had been practicing medicine for a long ... practitioners (99 per cent), according to Dr. Chaim Bell. ...
... (HealthDay News) -- Environmental pollutants such as dioxins, PCBs ... (atherosclerosis), according to a new study. Atherosclerosis is ... the most common cause of death in industrialized countries, ... They measured levels of persistent (long-lived and hard to ...
Cached Medicine News:Health News:Emerging pharmaceutical platform may pose risks to retinal health 2Health News:OU professors awarded $2.8 million for 4-year study on biodiversity in warmer climates 2Health News:Annual cost of violence pegged at $6.9 billion after women leave abusive partners, UBC research 2Health News:Hutchinson Center breaks ground for first collaborative cancer center in sub-Saharan Africa 2Health News:Hutchinson Center breaks ground for first collaborative cancer center in sub-Saharan Africa 3Health News:Hutchinson Center breaks ground for first collaborative cancer center in sub-Saharan Africa 4Health News:Hutchinson Center breaks ground for first collaborative cancer center in sub-Saharan Africa 5Health News:Researchers track number of doctors disciplined and why 2Health News:Environmental Toxins Linked to Hardening of Arteries 2
The balloon catheter is designed to pass over a previously placed .015 inch diameter wire guide included. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
... Technologies, The UroMax Ultra ia designed ... high pressure and low profile., Refolding ... a remarkably strong material that is ... materials., Non-Compliant Balloons, A compliant balloon ...
Medicine Products: